4//SEC Filing
Anders Jack 4
Accession 0001610717-25-000326
CIK 0001628171other
Filed
Sep 3, 8:00 PM ET
Accepted
Sep 4, 7:05 PM ET
Size
21.0 KB
Accession
0001610717-25-000326
Insider Transaction Report
Form 4
Anders Jack
Chief Financial Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-09-02−2,814→ 0 totalExercise: $2.68From: 2022-08-16Exp: 2028-09-26→ Common Stock (2,814 underlying) - Exercise/Conversion
Common Stock
2025-09-02$2.68/sh+2,814$7,542→ 116,128 total - Sale
Common Stock
2025-09-02$40.02/sh−4,762$190,560→ 113,314 total - Exercise/Conversion
Common Stock
2025-09-02$4.73/sh+1,948$9,214→ 118,076 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-03−3,189→ 0 totalExercise: $4.73From: 2023-08-09Exp: 2029-08-08→ Common Stock (3,189 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-02−1,948→ 3,189 totalExercise: $4.73From: 2023-08-09Exp: 2029-08-08→ Common Stock (1,948 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-03−2,049→ 15,418 totalExercise: $17.00From: 2024-02-12Exp: 2030-02-11→ Common Stock (2,049 underlying) - Exercise/Conversion
Common Stock
2025-09-03$4.73/sh+3,189$15,084→ 116,503 total - Exercise/Conversion
Common Stock
2025-09-03$17.00/sh+2,049$34,833→ 118,552 total - Sale
Common Stock
2025-09-03$40.17/sh−5,238$210,432→ 113,314 total
Footnotes (4)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024.
- [F2]Includes 54,213 RSUs.
- [F3]This transaction was executed in multiple trades in prices ranging from $40.00 to $40.05, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]This transaction was executed in multiple trades in prices ranging from $40.01 to $40.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Documents
Issuer
Revolution Medicines, Inc.
CIK 0001628171
Entity typeother
Related Parties
1- filerCIK 0001800668
Filing Metadata
- Form type
- 4
- Filed
- Sep 3, 8:00 PM ET
- Accepted
- Sep 4, 7:05 PM ET
- Size
- 21.0 KB